AU2020380926B2 - MrgprX2 antagonists and uses thereof - Google Patents

MrgprX2 antagonists and uses thereof

Info

Publication number
AU2020380926B2
AU2020380926B2 AU2020380926A AU2020380926A AU2020380926B2 AU 2020380926 B2 AU2020380926 B2 AU 2020380926B2 AU 2020380926 A AU2020380926 A AU 2020380926A AU 2020380926 A AU2020380926 A AU 2020380926A AU 2020380926 B2 AU2020380926 B2 AU 2020380926B2
Authority
AU
Australia
Prior art keywords
compound
composition
alkyl
acid
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020380926A
Other languages
English (en)
Other versions
AU2020380926A1 (en
Inventor
Ferda CEVIKBAS
Laura Gleave
Christopher Pearson
Nina Connelly URSINYOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermira Inc
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of AU2020380926A1 publication Critical patent/AU2020380926A1/en
Application granted granted Critical
Publication of AU2020380926B2 publication Critical patent/AU2020380926B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020380926A 2019-11-05 2020-11-05 MrgprX2 antagonists and uses thereof Active AU2020380926B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962931186P 2019-11-05 2019-11-05
US62/931,186 2019-11-05
US201962931576P 2019-11-06 2019-11-06
US62/931,576 2019-11-06
US202063046481P 2020-06-30 2020-06-30
US63/046,481 2020-06-30
PCT/US2020/059228 WO2021092264A1 (en) 2019-11-05 2020-11-05 MrgprX2 ANTAGONISTS AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2020380926A1 AU2020380926A1 (en) 2022-05-26
AU2020380926B2 true AU2020380926B2 (en) 2026-07-16

Family

ID=73740488

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020380926A Active AU2020380926B2 (en) 2019-11-05 2020-11-05 MrgprX2 antagonists and uses thereof

Country Status (8)

Country Link
US (1) US20230002336A1 (cg-RX-API-DMAC7.html)
EP (1) EP4055011A1 (cg-RX-API-DMAC7.html)
JP (1) JP7787811B2 (cg-RX-API-DMAC7.html)
CN (1) CN114728919B (cg-RX-API-DMAC7.html)
AU (1) AU2020380926B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159633A1 (cg-RX-API-DMAC7.html)
IL (1) IL292693B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021092264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850094B (zh) * 2022-09-07 2025-02-11 北华航天工业学院 一种利用1,2-环氧丁烷合成β-氨基醇的方法
WO2025002360A1 (zh) * 2023-06-30 2025-01-02 北京普祺医药科技股份有限公司 一种mrgprx2拮抗剂、药物组合物以及其用途
US20250084063A1 (en) 2023-08-18 2025-03-13 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025163462A1 (ko) * 2024-02-02 2025-08-07 삼진제약주식회사 헤테로고리를 갖는 mrgprx2((mas-related g-protein coupled receptor member x2) 길항제 유도체와 이의 용도
WO2025222076A1 (en) 2024-04-19 2025-10-23 Kyorin Pharmaceutical Co., Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as mrgprx2 antagonists for the treatment of inflammatory diseases
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
US12630562B2 (en) 2024-08-07 2026-05-19 Arcus Biosciences, Inc. Piperidylurea compounds and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
WO2009149858A1 (de) * 2008-06-13 2009-12-17 Bayer Cropscience Ag Neue heteroaromatische amide und thioamide als schädlingsbekämpfungsmittel
WO2012076989A1 (en) * 2010-12-09 2012-06-14 Wockhardt Limited Ketolide compounds
WO2013049559A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
EP2952096A1 (en) * 2013-01-30 2015-12-09 Sumitomo Chemical Company, Limited Method for controlling arthropod pest
WO2018160878A1 (en) * 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152442A (en) * 1975-06-05 1979-05-01 Lilly Industries Limited Certain acylamino-oxa (or thia) diazoles in treatment of hypersensitivity conditions
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
EP0084665B1 (de) * 1982-01-22 1986-08-13 BASF Aktiengesellschaft Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
GB0308511D0 (en) * 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
BRPI0413709A (pt) * 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
DE102004009933A1 (de) * 2004-02-26 2005-09-15 Merck Patent Gmbh Verwendung von Thiadiazolharnstoffderivaten
EP2125799A1 (en) 2007-02-28 2009-12-02 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
US8377639B2 (en) * 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
WO2015089327A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN107001362A (zh) * 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
WO2009149858A1 (de) * 2008-06-13 2009-12-17 Bayer Cropscience Ag Neue heteroaromatische amide und thioamide als schädlingsbekämpfungsmittel
WO2012076989A1 (en) * 2010-12-09 2012-06-14 Wockhardt Limited Ketolide compounds
WO2013049559A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
EP2952096A1 (en) * 2013-01-30 2015-12-09 Sumitomo Chemical Company, Limited Method for controlling arthropod pest
WO2018160878A1 (en) * 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1355717-46-2; STN Entry Date 7 February 2012 *
CAS Registry Number 1389735-91-4; STN Entry Date 12 August 2012 *
CAS Registry Number 1797794-23-0; STN Entry Date 9 July 2015 *
CAS Registry Number 2059876-46-7; STN Entry Date 26 January 2017 *
CAS Registry Number 2071484-66-5; STN Entry Date 16 February 2017 *
CAS Registry Number 2072573-53-4; STN Entry Date 20 February 2017 *
CAS Registry Number 2072672-14-9; STN Entry Date 20 February 2017 *
CAS Registry Number 2072939-65-0; STN Entry Date 21 February 2017 *
CAS Registry Number 2072967-38-3; STN Entry Date 21 February 2017 *
CAS Registry Number 2373852-96-9; STN Entry Date 4 September 2019 *
SYNTHESIS, 2010, vol. 2010, no. 06, pages 967 - 970. *

Also Published As

Publication number Publication date
CN114728919B (zh) 2025-12-30
IL292693B1 (en) 2026-05-01
AU2020380926A1 (en) 2022-05-26
CA3159633A1 (en) 2021-05-14
WO2021092264A1 (en) 2021-05-14
IL292693A (en) 2022-07-01
JP2022554392A (ja) 2022-12-28
CN114728919A (zh) 2022-07-08
US20230002336A1 (en) 2023-01-05
EP4055011A1 (en) 2022-09-14
JP7787811B2 (ja) 2025-12-19